Oral Biology Department, Faculty of Dentistry, Minia University, Minia, Egypt.
Diagn Pathol. 2008 Nov 20;3:45. doi: 10.1186/1746-1596-3-45.
Head and neck cancer including oral cancer is considered to develop by accumulated genetic alterations and the major pathway is cancerization from lesions such as intraepithelial dysplasia in oral leukoplakia and erythroplakia. The relationship of proliferation markers with the grading of dysplasia is uncertain. The involvement of EBV in oral carcinogenesis is not fully understood.
The present study was designed to investigate the role of EBV and DNA Topoisomerase II proportional (DNA-Topo II proportional) during oral carcinogenesis and to examine the prognostic significance of these protein expressions in OSCCs.
Using specific antibodies for EBV and DNA-Topo II proportional, we examined protein expressions in archival lesion tissues from 16 patients with oral epithelial dysplasia, 22 oral squamous cell carcinoma and 20 normal oral mucosa by immunohistochemistry. Clinical information was obtained through the computerized retrospective database from the tumor registry.
DNA-Topo II proportional was expressed in all examined specimens. Analysis of Variance ANOVA revealed highly significant difference (P < 0.01) in young aged labial tissues and significant (P < or = 0.05) in gingival and not significant (P > 0.05) in inferior surface of tongue and in hard palatal tissues. Significant differences were observed between OEDs and NSE (P < 0.001) and SCCs and controls (P < 0.001), also, significant differences could be observed between SCCs and OEDs. DNA-Topo II proportional expression was significantly higher in tumors of low differentiation versus tumors of moderate and high differentiation (P < 0.001), DNA-Topo II proportional expression was correlated with age, tumor size, tumor stage, node metastasis and tumor differentiation, but not with gender and tumor site. None of normal squamous epithelium (NSE) expressed EBV. Heterogeneous reactivity for EBV was observed through the series of dysplasia and squamous cell carcinoma. Its expression increased progressively with lymph node metastasis and low tumor differentiation, but no significant association could be observed with other clinicopathological parameters. EBV protein expression was increased with elevated Topo II-proportional LI in OEDs and OSCCs. A tendency to positive correlation between EBV and Topo II proportional, variant expression was observed in OEDs but not in OSCCs.
EBV and DNA Topo II-alphaLI expression are possible indicators in oral carcinogenesis and may be valuable diagnostic and prognostic indices in oral carcinoma.
头颈部癌症包括口腔癌被认为是由遗传改变的积累而发展的，主要途径是从口腔白斑和红斑病的上皮内异型增生等病变进行癌变。增殖标志物与异型增生分级的关系尚不确定。EBV 在口腔癌变中的作用尚未完全了解。
本研究旨在探讨 EBV 和 DNA 拓扑异构酶 II 比例（DNA-Topo II 比例）在口腔癌变过程中的作用，并研究这些蛋白表达在口腔鳞状细胞癌中的预后意义。
使用针对 EBV 和 DNA-Topo II 比例的特异性抗体，我们通过免疫组织化学法检测了 16 例口腔上皮异型增生、22 例口腔鳞状细胞癌和 20 例正常口腔黏膜存档病变组织中的蛋白表达。临床信息通过肿瘤登记处的计算机化回顾性数据库获得。
DNA-Topo II 比例在所有检查标本中均有表达。方差分析（ANOVA）显示，唇黏膜年轻组织有显著差异（P < 0.01），牙龈组织有显著差异（P < 0.05），舌下部和硬腭组织无显著差异（P > 0.05）。OED 与 NSE 之间（P < 0.001）和 SCC 与对照组之间（P < 0.001）有显著差异，SCC 与 OED 之间也有显著差异。低分化肿瘤的 DNA-Topo II 比例表达显著高于中高分化肿瘤（P < 0.001），DNA-Topo II 比例表达与年龄、肿瘤大小、肿瘤分期、淋巴结转移和肿瘤分化相关，但与性别和肿瘤部位无关。正常鳞状上皮（NSE）均不表达 EBV。在异型增生和鳞状细胞癌的系列中观察到 EBV 的异质性反应。其表达随淋巴结转移和低肿瘤分化而逐渐增加，但与其他临床病理参数无显著相关性。在 OED 和 OSCC 中，EBV 蛋白表达随 Topo II 比例的升高而升高。在 OED 中观察到 EBV 与 Topo II 比例之间存在正相关的趋势，但在 OSCC 中则没有。
EBV 和 DNA 拓扑异构酶 IIαLI 的表达可能是口腔癌变中的指标，并可能成为口腔癌有价值的诊断和预后指标。
